A first-of-its-kind study will use ultrasound and light therapies to investigate targeted treatment of Alzheimer’s disease, ...

SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

A class of drugs used to treat diabetes has been linked to a 20% lower risk of dementia and Parkinson's disease. | ...

A new study by scientists at Nottingham Trent University will use non-invasive techniques to investigate the targeted ...

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...

Around 55 million people globally are affected by dementia, with Alzheimer's disease responsible for 70% of these cases. The ...

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By ...

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.